Skip to main content
. 2017 Mar 30;8(27):43953–43966. doi: 10.18632/oncotarget.16693

Figure 5. SNORD47 sensitized U87-MG and U251 cells to temozolomide treatment.

Figure 5

(A) The IC50 assay was taken to measure the inhibitory concentration of temozolomide on U87-MG and U251 glioma cells. (B,C) The proliferation of NC and SNORD47 glioma cells under temozolomide (200uM) treatment was measured by CCK8 analysis. (D,E,F) The cell cycle distribution of NC and SNORD47 glioma cells under temozolomide treatment was examined by flow cytometry. *P < 0.05 (Student's t test) compared with the control group.